December 13, 2018: Francis Medical announces the completion of a $18.0 million round of Series A funding. Arboretum Ventures led the Series A with co-investments from H2Oey Ventures (an affiliate of Solas BioVentures Fund), Tonkawa, and Boston Scientific. Francis Medical plans to use this capital to further develop the company's cancer ablation therapy
The Vanquish® Water Vapor Ablation System has been cleared as a tool for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.